NIFTY 50

Suven Life Sciences evaluating sale of demerged CRAMS arm

Updated : February 12, 2020 01:41 PM IST

According to its 2019 annual report, Suven Life Sciences posted total revenues of around Rs 688 crores and a net profit of around Rs 150 crores.
The CRAMS vertical comprises four segments, namely Base CRAMS ( which accounts for 45 percent of the total revenues), Commercial CRAMS, Specialty Chemicals, and Contract Technical Services.

You May Also Like

Live TV